Replies to post #213668 on Biotech Values

[DewDiligence]

IDRA -27% on sale of 38.3M* shares@$1.50—a 26% discount to yesterday’s close:

https://finance.yahoo.com/news/idera-pharmaceuticals-announces-pricing-public-110000699.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

MRTX tightens focus to Sitravatinib/KRAS programs—Glesatinib development discontinued:

https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-advancement-of-first-in-class-opportunities-with-sitravatinib-and-kras-inhibitor-programs-300554979.html

Sitravatinib is the drug that showed an ORR of 27% (3/11) when combined with Opdivo in NSCLC PD-1 failures (#msg-134629963).